| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8758836 | Journal of the Chinese Medical Association | 2018 | 6 Pages |
Abstract
For a naïve patient in the new DAA era, the PegIFN/RBV treatment might be conserved for those with all favorable risk parameters, considering the treatment duration and cost per SVR, in the resource-constrained countries.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Pei-Chien Tsai, Ta-Wei Liu, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming-Lung Yu,